Type 2 diabetes is associated with an increased risk of cardiovascular complications, including coronary heart disease, stroke and heart failure. Effective management of these risks is essential to improve patients’ prognosis. SGLT2 inhibitors have shown significant benefits in reducing cardiovascular risk in patients with type 2 diabetes.
Mechanism of action of SGLT2 inhibitors
SGLT2 inhibitors act by blocking the reabsorption of glucose in the proximal renal contort tube, facilitating the elimination of glucose through the urine and, implicitly, lowering blood sugar. In addition to the hypoglycaemic effect, they induce weight loss and reduce blood pressure, helping to improve cardiovascular risk factors.
Cardiovascular benefits of SGLT2 inhibitors
Clinical trials have shown multiple cardiovascular benefits of SGLT2 inhibitors:
- Reduction of major cardiovascular events: A significant decrease in the risk of major cardiovascular events, such as myocardial infarction and stroke, has been observed in patients treated with SGLT2 inhibitors.
- Decreased hospitalizations for heart failure: These drugs have shown a reduction in the risk of hospitalization due to heart failure, regardless of the previous presence of cardiovascular disease.
- Renal protection: SGLT2 inhibitors provide renal benefits, slowing the progression of chronic kidney disease, which indirectly contributes to reducing cardiovascular risk.
Possible mechanisms of cardiovascular benefits
The cardioprotective effects of SGLT2 inhibitors can be attributed to several mechanisms:
- Osmotic diuresis and natriuresis: These lead to a reduction in intravascular volume and blood pressure, reducing the load on the heart.
- Improving endothelial function: By reducing oxidative stress and inflammation, the function of blood vessels improves.
- Changing cardiac energy metabolism: The use of ketone bodies as an energy source is promoted, which can improve the energy efficiency of the myocardial.
Clinical recommendations
Current guidelines recommend the use of SGLT2 inhibitors in patients with DZ2 and increased cardiovascular risk, especially in those with heart failure or chronic kidney disease. It is essential that doctors evaluate the individual profile of each patient to optimize antidiabetic therapy.
How can www.diabeta.ro help?
platform Diabeta provides doctors with quick access to essential information about the use of SGLT2 inhibitors and other antidiabetic treatments. Through it, doctors can:
- Quickly access updated SPCs: Details of indications, contraindications, drug interactions and recommended doses for SGLT2 inhibitors.
- Consult clinical guides: The platform includes updated guides detailing the use of SGLT2 inhibitors in reducing cardiovascular risk.
By integrating the resources offered by Diabeta In daily practice, doctors can ensure optimal management of patients with type 2 diabetes and increased cardiovascular risk.
SGLT2 inhibitors are a valuable class of drugs in DZ2 management, offering significant benefits in reducing cardiovascular risk. Their integration into the regimen, along with lifestyle changes and control of other risk factors, can significantly improve patients’ prognosis.
Diabeta was developed by a Romanian company, Apollo Technologies, specialized in creating professional applications based on artificial intelligence. The application is made available to doctors in professional medical communities administered by People and Companies, with the support of the partners Novo Nordisk, Boehringer Ingelheim and Medtronic.
